BioNTech to Host AI Day as an Edition of its Innovation Series on October 1, 2024
Rhea-AI Summary
BioNTech SE (Nasdaq: BNTX) and its AI company InstaDeep are set to host an AI Day as part of BioNTech's Innovation Series on October 1, 2024, in London. The event, starting at 09:00 a.m. EDT (3:00 p.m. CEST), will showcase the companies' AI strategy, capabilities, and its application in BioNTech's pipeline and internal processes.
A live webcast will be available for viewers, with a replay accessible on BioNTech's website for one year following the event. This presentation aims to provide insights into how BioNTech is leveraging AI technologies to advance its biopharmaceutical research and development efforts.
Positive
- BioNTech is demonstrating commitment to AI integration in its operations
- The event showcases BioNTech's innovation and technological advancements
- Potential for increased investor interest due to focus on AI applications in biotech
Negative
- None.
News Market Reaction
On the day this news was published, BNTX gained 1.00%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MAINZ, Germany, September 17, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host an AI Day, an edition of BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Tuesday, October 1st, 2024 in London, United Kingdom. The event will provide an overview of BioNTech’s and InstaDeep’s AI strategy and capabilities, and the application of AI in BioNTech’s pipeline and internal processes.
The live webcast of the event will be available via this link.
A replay of the webcast will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year after.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
CONTACTS
Media Relations
Jasmina Alatovic
+49 (0) 6131 9084 1513
Media@biontech.de
Investor Relations
Victoria Meissner, M.D.
Investors@biontech.de
FAQ
When is BioNTech (BNTX) hosting its AI Day event?
What will be discussed at BioNTech's (BNTX) AI Day event?
How can investors access BioNTech's (BNTX) AI Day presentation?
What is the significance of BioNTech's (BNTX) AI Day for investors?
